Europe — EMA
Nintedanib Teva
GNH USA supplies Nintedanib Teva (Nintedanib), a tyrosine kinase inhibitor for idiopathic pulmonary fibrosis, scleroderma‑ILD and NSCLC. Request a quote.
Request sourcing
What is Nintedanib?
Nintedanib, the active ingredient in Nintedanib Teva, is a tyrosine kinase inhibitor presented as a tablet for oral use. It targets key pathways involved in fibrotic lung disease and certain cancers, and is indicated for the treatment of idiopathic pulmonary fibrosis, systemic sclerosis‑associated interstitial lung disease, and specific non‑small cell lung cancer subtypes.
GNH USA supplies Nintedanib Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, oncology centres and clinics worldwide, ensuring quality assurance and regulatory compliance across all markets.
What is Nintedanib used for?
Nintedanib is used in fibrotic lung disorders and selected oncologic indications, where it modulates disease‑driving pathways.
Idiopathic pulmonary fibrosis: slows decline in lung function and reduces disease progression. Systemic sclerosis‑associated interstitial lung disease: improves pulmonary function and delays worsening. Non‑small cell lung cancer: used in combination therapy to inhibit tumor growth.
What are the side effects of Nintedanib?
Nintedanib may cause a range of adverse reactions, which are categorized by frequency and severity.
Common Side Effects: - Diarrhea: frequent loose stools. - Nausea: mild to moderate sensation. - Vomiting: occasional episodes. - Elevated liver enzymes: increased ALT/AST levels.
Serious or Rare Side Effects: - Hepatotoxicity: severe liver injury requiring monitoring. - Bleeding events: heightened risk of gastrointestinal or intracranial hemorrhage. - Cardiovascular events: arterial thromboembolism or myocardial infarction.
What precautions apply to Nintedanib?
When prescribing Nintedanib, clinicians should consider several safety measures.
Liver function monitoring: perform baseline and periodic ALT/AST tests. Bleeding risk assessment: avoid concomitant anticoagulants unless necessary. Gastrointestinal health: monitor for severe diarrhea or colitis. Pregnancy and lactation: use only if benefits outweigh risks; consult physician. Drug interactions: review concomitant medications for CYP3A4 substrates. Store at below 25°C: keep in original packaging, protect from moisture and light.
What does Nintedanib interact with?
Nintedanib can interact with other medicines, requiring careful management.
Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase nintedanib exposure. - Anticoagulants (e.g., warfarin, direct oral anticoagulants): heightened bleeding risk. - P‑glycoprotein inhibitors (e.g., verapamil): may raise plasma levels.
Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy. - Antiplatelet agents (e.g., aspirin, clopidogrel): monitor for bleeding. - Diuretics: watch for dehydration that can worsen gastrointestinal side effects.
